BNP Paribas Financial Markets Raises Holdings in Replimune Group, Inc. (NASDAQ:REPL)

BNP Paribas Financial Markets boosted its stake in Replimune Group, Inc. (NASDAQ:REPL) by 81.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,011 shares of the company’s stock after purchasing an additional 6,748 shares during the period. BNP Paribas Financial Markets’ holdings in Replimune Group were worth $165,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of REPL. Quest Partners LLC increased its stake in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Algert Global LLC raised its stake in shares of Replimune Group by 5.4% during the second quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after acquiring an additional 4,340 shares during the last quarter. Creative Planning boosted its holdings in shares of Replimune Group by 28.7% during the third quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after purchasing an additional 4,699 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC grew its stake in shares of Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock worth $646,000 after purchasing an additional 5,410 shares during the last quarter. Institutional investors own 92.53% of the company’s stock.

Wall Street Analyst Weigh In

REPL has been the subject of a number of recent analyst reports. BMO Capital Markets upped their price target on Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a research report on Friday, November 22nd. Roth Capital upgraded Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. JPMorgan Chase & Co. raised their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research report on Friday, November 22nd. Finally, Jefferies Financial Group upped their price objective on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Replimune Group has an average rating of “Buy” and an average target price of $17.29.

Insider Buying and Selling

In other news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the transaction, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.80% of the stock is currently owned by insiders.

Replimune Group Price Performance

Shares of REPL stock opened at $11.72 on Wednesday. The business’s fifty day moving average is $12.22 and its 200 day moving average is $10.58. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The stock has a market cap of $801.85 million, a price-to-earnings ratio of -3.84 and a beta of 1.26. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.07. Research analysts expect that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.